



24 Machine learning

25 U-Net

26 Corresponding author: Ana Tiganescu

27 Leeds Institute of Cardiovascular and Metabolic Medicine

28 School of Medicine, LIGHT Building, Clarendon Way

29 University of Leeds, LS2 9JT, UK

30 0113 34 38336

31 a.tiganescu@leeds.ac.uk

32 Disclosure Summary: I certify that neither I nor my co-authors have a conflict of interest as described

33 above that is relevant to the subject matter or materials included in this Work.

## 34 Abstract

35 Type 2 diabetes mellitus is associated with impaired wound healing, which contributes substantially  
36 to patient morbidity and mortality. Glucocorticoid (stress hormone) excess is also known to delay  
37 wound repair. Optical coherence tomography (OCT) is an emerging tool for monitoring healing by  
38 “virtual biopsy”, but largely requires manual analysis, which is labour-intensive and restricts data  
39 volume processing. This limits the capability of OCT in clinical research.

40 Using OCT data from the GC-SHEALD trial, we developed a novel machine learning algorithm for  
41 automated volumetric quantification of discrete morphological elements of wound healing (by 3mm  
42 punch biopsy) in patients with type 2 diabetes. This was able to differentiate between early / late  
43 granulation tissue, neo-epidermis and clot structural features and quantify their volumetric  
44 transition between day 2 and day 7 wounds. Using OCT, we were able to visualize differences in  
45 wound re-epithelialisation and re-modelling otherwise indistinguishable by gross wound morphology  
46 between these time points. Automated quantification of maximal early granulation tissue showed a  
47 strong correlation with corresponding (manual) GC-SHEALD data. Further, % re-epithelialisation was  
48 improved in patients treated with oral AZD4017, an inhibitor of systemic glucocorticoid-activating  
49  $11\beta$ -hydroxysteroid dehydrogenase type 1 enzyme action, with a similar trend in neo-epidermis  
50 volume.

51 Through the combination of machine learning and OCT, we have developed a highly sensitive and  
52 reproducible method of automated volumetric quantification of wound healing. This novel approach  
53 could be further developed as a future clinical tool for the assessment of wound healing e.g. diabetic  
54 foot ulcers and pressure ulcers.

## 55 Introduction

56 In 2017/2018, the UK National Health Service (NHS) treated 3.8 million people with wounds, 1 in 3 of  
57 which failed to heal within a year (1). Direct costs were over £8 billion, with the majority for chronic  
58 wound care. Of concern, annual wound prevalence has increased by over 70% between 2012 and  
59 2018, highlighting the urgent need to improve monitoring, management and treatment (1).

60 The financial burden of chronic wounds is mainly attributed to amputations in patients with diabetes  
61 (2). Since 1980, global rates of type 2 diabetes mellitus (T2DM) have more than quadrupled and the  
62 majority of countries remain unlikely to attain United Nation targets (3, 4). Chronic wounds (e.g.  
63 diabetic foot ulcers) affect around 5% of people with diabetes at any one time and have a 5-year  
64 mortality of up to 55% (5, 6). Affected individuals have a poor quality of life (2, 7) and the indirect  
65 costs associated with lost productivity are much greater than those of treatment (8-10).

66 Stress hormone (glucocorticoid) excess also leads to chronic wounds (11, 12). Glucocorticoids affect  
67 virtually every phase of wound healing, including inflammation (13, 14), re-epithelialization (15, 16),  
68 granulation tissue formation (16) and extracellular matrix (collagen) synthesis, processing and  
69 remodelling (17, 18). Local glucocorticoid levels are regulated by 11 $\beta$ -hydroxysteroid dehydrogenase  
70 (11 $\beta$ -HSD) isozymes which activate (11 $\beta$ -HSD1) and deactivate (11 $\beta$ -HSD2) both natural and  
71 synthetic corticosteroid forms (19-23). Through these enzymes, peripheral exposure to  
72 glucocorticoids is maintained independently of circulating hormone levels (24). We previously found  
73 increased 11 $\beta$ -HSD1 during normal mouse wound healing (20) and Brazel *et al.* recently found this to  
74 be exacerbated in diabetic (*db/db*) mice (25). Subsequently we (and others) reported accelerated  
75 healing in aged 11 $\beta$ -HSD1 knockout mice and following topical 11 $\beta$ -HSD1 inhibition in healthy mice  
76 and those treated with the oral glucocorticoid corticosterone (21, 22, 26). Improved wound healing  
77 following 11 $\beta$ -HSD1 blockade has also been found in animal models of diabetes (27) but this had not  
78 been explored in man.

79 Our recent double-blind, randomised controlled trial (GC-SHEALD) in adults with T2DM treated with  
80 the selective 11 $\beta$ -HSD1 inhibitor AZD4017 for 35 days found that wounds were 48% smaller at day 2  
81 compared to placebo (28). This was based on maximal early granulation tissue width by optical  
82 coherence tomography (OCT), although no difference was found in maximal blood clot / scab depth  
83 at day 7 post-wounding (early granulation tissue was undetectable in day 7 wounds).

84 Optical coherence tomography (OCT) is a real-time tomographic imaging technique using low  
85 intensity infrared light to visualise living tissues. This non-invasive method enables high-resolution  
86 two- and three-dimensional cross-sectional imaging (analogous to histology) and is a validated  
87 method of monitoring skin structure and wound healing (29-33). However, OCT application has so  
88 far been restricted to manual annotation of two-dimensional scans which is time consuming,  
89 restricts the number of samples or time points that can be processed and limits scientific insights.

90 Here, we report the novel application of machine learning to identify and quantify key morphological  
91 features of wound healing in 3D, validated by manual two-dimensional analysis. This was validated  
92 using OCT outputs from the GC-SHEALD pilot phase 2b trial to analyse the wound healing response  
93 to systemic 11 $\beta$ -HSD1 inhibition in patients with T2DM.

## 94 Results

### 95 Machine Learning

#### 96 Reliability

#### 97 Wound Morphology

98 An illustrative example of typical machine-annotated outputs from days 2 and 7 post-wounding are  
99 shown (Figure 1). Wound morphology was classified into 4 sub-types based on key morphological  
100 features; 1) early granulation tissue, exhibiting a “honeycomb” appearance as fibrinolysis breaks  
101 down the clot and is replaced with early extracellular matrix, 2) late granulation tissue, displaying a  
102 uniform horizontal alignment, 3) neo-epidermis, extending from the wound margins at day 2 and  
103 adjoining beneath the clot by day 7 and 4) clot, forming a plug over the wound.

104 Automated annotation reliability was assessed for all scans. Investigator agreement with machine  
105 annotation accuracy (inter-observer reliability) was excellent (ICC>0.8) for all sub-types with  
106 ICC>0.95 for early granulation, late granulation and neo-epidermal tissue and ICC>0.85 for clot  
107 tissue. Altman plots, bias and limit of agreement for reliability of wound sub-type annotations are  
108 shown in Figure 2.

#### 109 Validation

110 A strong correlation ( $r=0.81$ ,  $p<0.001$ ) was observed between machine learning outputs and manual  
111 measurement of maximal early granulation tissue width (mm) at treatment days 2 and 30 (Figure  
112 3a). However, this was not observed between machine learning outputs and manual measurement  
113 of maximal clot depth at treatment days 7 and 35 (Figure 3b).

### 114 Wound Morphology

#### 115 Gross Morphology and Re-epithelialization

116 Gross wound area was largely comparable between treatments and time points. Using this indicator,  
117 healing improved from 37% to 49% between day 2 and day 7 in the placebo (PBO) group ( $p<0.05$ ) in  
118 biopsies conducted at day 0 (set 1), but no improvement was observed between day 2 and day 7  
119 wounds in the second round of biopsies conducted on treatment day 28 (set 2). Similarly, no  
120 treatment effect was discernible at either time point (Figure 4a and 4c).

121 Manual analysis of matched OCT images revealed a large increase in % re-epithelialization  
122 (mean $\pm$ SD) at day 7 vs. day 2 post-wounding in both PBO and 11 $\beta$ -HSD1 inhibitor AZD4017 (AZD)  
123 treated groups (PBO set 1: 99.7 $\pm$ 0.8 vs. 56 $\pm$ 27, set 2: 99.3 $\pm$ 2.4 vs. 64.6 $\pm$ 19.7, both  $p<0.001$ , and AZD  
124 set 1: 100 $\pm$ 0 vs. 65.3 $\pm$ 23.6,  $p<0.001$ , set 2: 100 $\pm$ 0 vs. 84.7 $\pm$ 13.5, all  $p<0.01$ , Figure 4b and 4d).

125 At 7 days post-wounding, re-epithelialization was complete in most cases and hence no conclusion  
126 on treatment effect could be made. However, in day 2 wounds after 30 days treatment, re-  
127 epithelialization was 30% greater in the AZD group ( $p<0.05$ ).

#### 128 Automated volumetric analysis

129 Representative histograms displaying wound sub-type area for each scan frame (120 frames per  
130 scan) by treatment and treatment day are presented in Figure 5.

### 131 Early Granulation Tissue

132 Early granulation tissue volume (mean±SD) was significantly decreased at day 7 vs. day 2 post-  
133 wounding in both PBO and AZD treated groups and in both sets of biopsies (PBO set 1: 0.09±0.09 vs.  
134 1.56±0.7, set 2: 0.13±0.17 vs. 1.38±0.7, both p<0.001 and AZD set 1: 0.1±0.1 vs. 1.36±0.7, p<0.001,  
135 set 2: 0.11±0.2 vs. 0.96±0.6, p<0.01, Figure 6a).

136 At 7 days post-wounding there was no evidence of an AZD effect and resolution of early granulation  
137 tissue was mostly complete in all cases. In day 2 wounds after 30 days treatment, the effect with  
138 11β-HSD1 inhibitor treatment was in the expected direction, but not statistically significant (p=0.48).  
139 This was also the case in day 2 wounds after 2 days treatment (p=0.93).

### 140 Late Granulation Tissue

141 A similar effect was observed for late granulation tissue volume (mean±SD), although volumes were  
142 higher overall, indicative of a more advanced stage of healing (as early granulation tissue is  
143 processed by resident fibroblasts to a more mature form). Day 7 vs. day 2 post-wounding late  
144 granulation tissue volume was PBO set 1: 0.87±0.6 vs. 2.12±0.8, p<0.001, set 2: 0.91±0.6 vs.  
145 1.54±0.7, p=0.25 and AZD set 1: 0.81±0.8 vs. 1.75±0.5, p<0.05, set 2: 0.72±0.7 vs. 1.34±0.7, p<0.001  
146 (Figure 6b).

147 At 2 days post-wounding and 2 days treatment, there was evidence of an effect with AZD4017 in the  
148 expected direction, but this was not statistically significant (p=0.53). No evidence of an effect was  
149 present at other time points (although variance was relatively high).

### 150 Neo-epidermis

151 In contrast to granulation tissue, neo-epidermis volume (mean±SD) was significantly increased at day  
152 7 vs. day 2 post-wounding in all groups (PBO set 1: 1.46±0.5 vs. 0.9±0.6, p<0.01, set 2: 1.29±0.5 vs.  
153 0.65±0.2, p<0.001 and AZD set 1: 1.38±0.4 vs. 0.87±0.4, p<0.01, set 2: 1.39±0.5 vs. 0.92±0.3, p<0.05,  
154 Figure 6c).

155 At 7 days post-wounding there was no evidence of an AZD effect and re-epithelialization was mostly  
156 complete in all cases. In day 2 wounds after 30 days treatment, there was a strong trend towards  
157 42% greater neo-epidermal volume in the 11β-HSD1 inhibitor treatment group (p=0.09). This was  
158 not apparent in day 2 wounds after 2 days treatment (p=0.99).

### 159 Clot

160 Similarly to the neo-epidermis, clot volume (mean±SD) was found to significantly increase in day 7  
161 vs. day 2 wounds, consistent with a more advanced stage of healing (PBO set 1: 2.68±1 vs. 1.28±1.6,  
162 set 2: 2.35±0.6 vs. 0.91±0.7, both p<0.001 and AZD set 1: 2.73±0.7 vs. 1.16±0.7, p<0.001, set 2:  
163 2.83±0.9 vs. 1.21±0.4, p<0.01, Figure 6d).

164 In day 7 wounds after 35 days treatment, the change in clot volume with AZD4017 was in the  
165 expected direction, but not statistically significant (p=0.45). This was also true in day 7 wounds after  
166 7 days treatment (p=0.99).

## 167 Discussion

168 OCT has recently been validated as a non-invasive method of monitoring skin wound healing though  
169 a “virtual biopsy” (29-33) but volumetric analysis and automated classification wound healing had  
170 not previously been described. Here, we applied machine learning for automated quantification of  
171 key morphological features during wound repair.

172 Our findings suggest that OCT is a more sensitive method of monitoring wound healing, able to  
173 visualise key morphological features of wound healing otherwise undetectable using traditional  
174 imaging (e.g. digital photography). Despite a small sample size, we detected significant reductions in  
175 early clot / early granulation tissue and late granulation tissue with a concomitant increase in neo-  
176 epidermis and clot tissue volumes in day 7 wounds compared to day 2. These findings were highly  
177 reproducible between the two sets of biopsies in our cohort and importantly, reflect the normal  
178 healing chronology measured by two-dimensional OCT (29). However, our novel method of  
179 automated quantification has the key advantage of measuring the entire volume of specific wound  
180 healing features, which may not be accurately reflected by two-dimensional measurement.

181 Given the complex nature of the wound environments, inter-observer reliability (i.e. investigator  
182 agreement with machine annotation) was excellent for early granulation tissue, late granulation  
183 tissue and neo-epidermis, and good for clot (which exhibited a more heterogeneous morphology).  
184 Results were validated against manually derived measurements of early granulation tissue maximal  
185 width and maximal clot depth which were the only reportable healing outcomes of GC-SHEALD. The  
186 former correlated well with automated measures of volume but this was not evident for clot, likely  
187 due to the much narrower data range and lower machine learning sensitivity.

188 Punch biopsy healing in our T2DM cohort was largely normal, with complete re-epithelialization by  
189 day 7 in most samples and full healing (including blood clot detachment) by day 28. This was not  
190 unexpected, as patients with active ulceration and more poorly controlled diabetes (i.e. the intended  
191 target population) were excluded from GC-SHEALD pending safety results (which now support a  
192 future trial in patients with diabetic foot ulcers). However, the inclusion of patients with relatively  
193 normal healing may limit the scope of AZD4017 effectiveness. This is supported by our pre-clinical  
194 finding that topical 11 $\beta$ -HSD1 inhibition partially restores normal healing in mice treated with oral  
195 corticosterone (active rodent glucocorticoid) but has no benefit on normal mouse healing (despite  
196 comparable 11 $\beta$ -HSD1 inhibition)(21).

197 Despite this limitation, we found a 30% improvement in re-epithelialization by AZD4017, with a  
198 comparable trend in neo-epidermis volume. These additional analyses (including an automated and  
199 unbiased method) strengthen the core GC-SHEALD wound healing outcome that AZD4017 reduced  
200 wound gap width by 48% (28). Our results are also in agreement with mechanistic findings that  
201 glucocorticoids impair epidermal re-epithelialization through suppression of keratinocyte growth  
202 factor signalling (15, 16). However, the statistical interpretations of our results are based on a  
203 relatively small sample size and findings should be considered preliminary. Based on treatment day  
204 30 results, estimated sample sizes of 43, 257, 12 and 37 per treatment group for early granulation,  
205 late granulation, neo-epidermis and clot (respectively) are anticipated to confirm the observed  
206 differences (90% power, alpha error 0.05).

207 In summary, our results demonstrate that automated volumetric quantification by OCT is a powerful  
208 technique, offering deeper insights into wound healing morphology. This now warrants further  
209 development in larger cohorts, with an extended acute wound healing time course in young healthy  
210 skin compared to complex wounds, such as diabetic foot ulcers. Through non-invasive monitoring of  
211 three-dimensional healing in real-time, clinicians could gain a more detailed understanding of  
212 treatment requirements, responses and disease-specific healing outcomes. Finally, our promising  
213 findings may lead to the discovery of novel prognostic biomarkers of healing for a more tailored  
214 approach to wound care management.

## 215 **Materials and Methods**

### 216 **Study Participants**

217 Data was acquired from the GC-SHEALD trial ([www.isrctn.com/ISRCTN74621291](http://www.isrctn.com/ISRCTN74621291) and  
218 <https://clinicaltrials.gov/ct2/show/NCT03313297>) with approval by the North West - Greater  
219 Manchester Central Research Ethics Committee (17/NW/0283) and following full informed consent.  
220 Briefly, participants were randomized in a double-blind manner to placebo (PBO, n=14) or 400mg bi-  
221 daily of the 11 $\beta$ -HSD1 inhibitor AZD4017 (AZD, n=14) for 35 days treatment. At days 0 and 28,  
222 wounds were induced by 2mm diameter full-thickness punch biopsy under local anaesthesia.  
223 Wounds were treated with a breathable dressing for 24 hours and imaged at 2- and 7-days post-  
224 wounding (treatment days 2, 7, 30 and 35).

### 225 **Optical Coherence Tomography**

226 Scans were obtained using a Michelson-Diagnostics (Maidstone, UK) VivoSight™ scanner capturing  
227 120 image frames 50 $\mu$ m apart (6mm). This was sufficient to capture each 2mm punch biopsy site in  
228 full. A total of 207 scans were available, taken from two biopsies at each time point per patient.  
229 Three scans were removed prior to machine learning input due to image acquisition anomalies e.g.  
230 both biopsies captured in one scan. Data outputs were screened for inter-observer reliability  
231 resulting in the exclusion of a further 17 scans, with the remaining scans representing 101/104  
232 (>97%) averaged patient time points as follows: PBO treatment day 2 (n=14), PBO treatment day 7  
233 (n=14), PBO treatment day 30 (n=11), PBO treatment day 35 (n=13), AZD treatment day 2 (n=14),  
234 AZD treatment day 7 (n=14), AZD treatment day 30 (n=12), PBO treatment day 35 (n=12).

235 Re-epithelialization data was based on surface OCT imaging data. Gross wound morphology was  
236 obtained by simultaneous aerial camera image capture during the OCT scan.

### 237 **Machine Learning**

238 Within each scan frame, 7 distinctive image sub-types were defined: neo-epidermis, clot, early and  
239 late granulation tissue, intact tissue (peripheral to the wound), active bleeding and non-tissue. We  
240 used a u-net based convolutional neural network for the image segmentation of each 2D OCT frame,  
241 and the ground truth labels are annotations of the 7 sub-types (34). We acknowledge that other  
242 networks can also be used, including variations of the u-net (35) or the GANs model (36) and for  
243 simplicity in this first study of OCT data, we used classical u-net architecture.

244 U-net model training used 84 OCT frames annotated with the above 7 image sub-types, chosen  
245 manually from 207 scans (each scan comprising 120 frames). The training sample therefore  
246 represented 0.34% of available frames used in the study. The u-net architecture was written in



247 Matlab 2019b, using a Linux cluster with three Tesla K80 GPUs training. This took 100 epochs with  
248 1344 iterations per epoch, using a stochastic gradient descent with momentum=0.9, optimising at an  
249 initial learning rate of 0.05. The Factor for L2 regularization was set to 0.0001. The minimum batch  
250 size was set to 16 images and the training data was shuffled at every epoch. The training took 3483  
251 minutes with a mini-batch accuracy of 85.85% at the final iteration.

252 The prediction of all samples was then performed using the trained model followed by a set of  
253 morphological operations to remove isolated pixels and small islands. Boundaries between classes  
254 were also smoothed with a Fourier descriptor. Considering the penetration depth of OCT scanner,  
255 we sampled to a depth of 1mm for each frame, calculating neo-epidermis, clot and granulation  
256 tissue area (mm<sup>2</sup>). Intact tissue, active bleeding (in a negligible number of samples) and non-tissue  
257 were excluded from the analysis. The areas were then multiplied by the scanning interval (50µm) for  
258 volumetric results (mm<sup>3</sup>).

### 259 **Statistical Methods**

260 All data groups followed a normal distribution. Grouped analyses were performed (95% confidence  
261 interval) using a two-way analysis of variance mixed-effects model with *post hoc* testing corrected  
262 for multiple comparisons using Sidak's test (GraphPad Prism, La Jolla, CA).

263 Correlations were analysed using Pearson's correlation testing (95% confidence interval).

### 264 **References and Notes**

- 265 1. J. F. Guest, G. W. Fuller, P. Vowden, Cohort study evaluating the burden of wounds to the  
266 UK's National Health Service in 2017/2018: update from 2012/2013. *BMJ Open* **10**, e045253  
267 (2020).
- 268 2. M. Olsson, K. Jarbrink, U. Divakar, R. Bajpai, Z. Upton, A. Schmidtchen, J. Car, The humanistic  
269 and economic burden of chronic wounds: A systematic review. *Wound repair and  
270 regeneration : official publication of the Wound Healing Society [and] the European Tissue  
271 Repair Society* **27**, 114-125 (2019).
- 272 3. M. K. Ali, K. M. Bullard, J. B. Saaddine, C. C. Cowie, G. Imperatore, E. W. Gregg, Achievement  
273 of goals in U.S. diabetes care, 1999-2010. *The New England journal of medicine* **368**, 1613-  
274 1624 (2013).
- 275 4. N. C. D. R. F. Collaboration, Worldwide trends in diabetes since 1980: a pooled analysis of  
276 751 population-based studies with 4.4 million participants. *Lancet* **387**, 1513-1530 (2016).
- 277 5. D. G. Armstrong, M. A. Swerdlow, A. A. Armstrong, M. S. Conte, W. V. Padula, S. A. Bus, Five  
278 year mortality and direct costs of care for people with diabetic foot complications are  
279 comparable to cancer. *J Foot Ankle Res* **13**, 16 (2020).
- 280 6. J. M. Robbins, G. Strauss, D. Aron, J. Long, J. Kuba, Y. Kaplan, Mortality rates and diabetic  
281 foot ulcers: is it time to communicate mortality risk to patients with diabetic foot ulceration?  
282 *J Am Podiatr Med Assoc* **98**, 489-493 (2008).
- 283 7. S. Pedras, R. Carvalho, M. G. Pereira, Predictors of quality of life in patients with diabetic  
284 foot ulcer: The role of anxiety, depression, and functionality. *J Health Psychol* **23**, 1488-1498  
285 (2018).
- 286 8. P. Cavanagh, C. Attinger, Z. Abbas, A. Bal, N. Rojas, Z. R. Xu, Cost of treating diabetic foot  
287 ulcers in five different countries. *Diabetes Metab Res Rev* **28 Suppl 1**, 107-111 (2012).
- 288 9. N. Hex, C. Bartlett, D. Wright, M. Taylor, D. Varley, Estimating the current and future costs of  
289 Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and  
290 productivity costs. *Diabetic medicine : a journal of the British Diabetic Association* **29**, 855-  
291 862 (2012).

- 292 10. A. American Diabetes, Economic costs of diabetes in the U.S. In 2007. *Diabetes care* **31**, 596-  
293 615 (2008).
- 294 11. E. Harris, A. Tiganescu, S. Tubeuf, S. L. Mackie, The prediction and monitoring of toxicity  
295 associated with long-term systemic glucocorticoid therapy. *Current rheumatology reports*  
296 **17**, 513 (2015).
- 297 12. A. C. DeVries, T. K. Craft, E. R. Glasper, G. N. Neigh, J. K. Alexander, 2006 Curt P. Richter  
298 award winner: Social influences on stress responses and health. *Psychoneuroendocrinology*  
299 **32**, 587-603 (2007).
- 300 13. A. M. Mercado, D. A. Padgett, J. F. Sheridan, P. T. Marucha, Altered kinetics of IL-1 alpha, IL-1  
301 beta, and KGF-1 gene expression in early wounds of restrained mice. *Brain, behavior, and*  
302 *immunity* **16**, 150-162 (2002).
- 303 14. R. M. Gallucci, T. Sugawara, B. Yucesoy, K. Berryann, P. P. Simeonova, J. M. Matheson, M. I.  
304 Luster, Interleukin-6 treatment augments cutaneous wound healing in immunosuppressed  
305 mice. *Journal of interferon & cytokine research : the official journal of the International*  
306 *Society for Interferon and Cytokine Research* **21**, 603-609 (2001).
- 307 15. B. Lee, C. Vouthounis, O. Stojadinovic, H. Brem, M. Im, M. Tomic-Canic, From an  
308 enhanceosome to a repressosome: molecular antagonism between glucocorticoids and EGF  
309 leads to inhibition of wound healing. *Journal of molecular biology* **345**, 1083-1097 (2005).
- 310 16. A. Sanchis, L. Alba, V. Latorre, L. M. Sevilla, P. Perez, Keratinocyte-targeted overexpression of  
311 the glucocorticoid receptor delays cutaneous wound healing. *PLoS one* **7**, e29701 (2012).
- 312 17. M. S. Bitar, T. Farook, S. Wahid, I. M. Francis, Glucocorticoid-dependent impairment of  
313 wound healing in experimental diabetes: amelioration by adrenalectomy and RU 486. *The*  
314 *Journal of surgical research* **82**, 234-243 (1999).
- 315 18. Y. Oishi, Z. W. Fu, Y. Ohnuki, H. Kato, T. Noguchi, Molecular basis of the alteration in skin  
316 collagen metabolism in response to in vivo dexamethasone treatment: effects on the  
317 synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases.  
318 *The British journal of dermatology* **147**, 859-868 (2002).
- 319 19. A. Tiganescu, M. Hupe, Y. J. Jiang, A. Celli, Y. Uchida, T. M. Mauro, D. D. Bikle, P. M. Elias, W.  
320 M. Holleran, UVB induces epidermal 11beta-hydroxysteroid dehydrogenase type 1 activity in  
321 vivo. *Experimental dermatology* **24**, 370-376 (2015).
- 322 20. A. Tiganescu, M. Hupe, Y. Uchida, T. Mauro, P. M. Elias, W. M. Holleran, Increased  
323 glucocorticoid activation during mouse skin wound healing. *The Journal of endocrinology*  
324 **221**, 51-61 (2014).
- 325 21. A. Tiganescu, M. Hupe, Y. Uchida, T. Mauro, P. M. Elias, W. M. Holleran, Topical 11 beta-  
326 Hydroxysteroid Dehydrogenase Type 1 Inhibition Corrects Cutaneous Features of Systemic  
327 Glucocorticoid Excess in Female Mice. *Endocrinology* **159**, 547-556 (2018).
- 328 22. A. Tiganescu, A. A. Tahrani, S. A. Morgan, M. Otranto, A. Desmouliere, L. Abrahams, Z.  
329 Hassan-Smith, E. A. Walker, E. H. Rabbitt, M. S. Cooper, K. Amrein, G. G. Lavery, P. M.  
330 Stewart, 11beta-Hydroxysteroid dehydrogenase blockade prevents age-induced skin  
331 structure and function defects. *The Journal of clinical investigation* **123**, 3051-3060 (2013).
- 332 23. A. Tiganescu, E. A. Walker, R. S. Hardy, A. E. Mayes, P. M. Stewart, Localization, age- and site-  
333 dependent expression, and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in  
334 skin. *The Journal of investigative dermatology* **131**, 30-36 (2011).
- 335 24. S. A. Morgan, E. L. McCabe, L. L. Gathercole, Z. K. Hassan-Smith, D. P. Lerner, I. J. Bujalska, P.  
336 M. Stewart, J. W. Tomlinson, G. G. Lavery, 11beta-HSD1 is the major regulator of the tissue-  
337 specific effects of circulating glucocorticoid excess. *Proceedings of the National Academy of*  
338 *Sciences of the United States of America* **111**, E2482-2491 (2014).
- 339 25. C. B. Brazel, J. C. Simon, J. P. Tuckermann, A. Saalbach, Inhibition of 11beta-HSD1 Expression  
340 by Insulin in Skin: Impact for Diabetic Wound Healing. *J Clin Med* **9**, (2020).
- 341 26. J. K. Youm, K. Park, Y. Uchida, A. Chan, T. M. Mauro, W. M. Holleran, P. M. Elias, Local  
342 blockade of glucocorticoid activation reverses stress- and glucocorticoid-induced delays in

- 343 cutaneous wound healing. *Wound repair and regeneration : official publication of the*  
344 *Wound Healing Society [and] the European Tissue Repair Society* **21**, 715-722 (2013).
- 345 27. M. Terao, H. Murota, A. Kimura, A. Kato, A. Ishikawa, K. Igawa, E. Miyoshi, I. Katayama,  
346 11beta-Hydroxysteroid dehydrogenase-1 is a novel regulator of skin homeostasis and a  
347 candidate target for promoting tissue repair. *PLoS one* **6**, e25039 (2011).
- 348 28. R. Ajjan, E. M. Hensor, K. Shams, F. Del Galdo, A. Abbas, J. Woods, R. J. Fairclough, L.  
349 Webber, L. Pegg, A. Freeman, A. Morgan, P. M. Stewart, A. E. Taylor, W. Arlt, A. Tahrani, D.  
350 Russell, A. Tiganescu, A randomised controlled pilot trial of oral 11 $\beta$ -HSD1 inhibitor AZD4017  
351 for wound healing in adults with type 2 diabetes mellitus. *medRxiv*,  
352 2021.2003.2023.21254200 (2021).
- 353 29. N. S. Greaves, B. Benatar, S. Whiteside, T. Alonso-Rasgado, M. Baguneid, A. Bayat, Optical  
354 coherence tomography: a reliable alternative to invasive histological assessment of acute  
355 wound healing in human skin? *The British journal of dermatology* **170**, 840-850 (2014).
- 356 30. J. Holmes, S. Schuh, F. L. Bowling, R. Mani, J. Welzel, Dynamic Optical Coherence  
357 Tomography Is a New Technique for Imaging Skin Around Lower Extremity Wounds. *The*  
358 *international journal of lower extremity wounds* **18**, 65-74 (2019).
- 359 31. N. S. Greaves, S. A. Iqbal, T. Hodgkinson, J. Morris, B. Benatar, T. Alonso-Rasgado, M.  
360 Baguneid, A. Bayat, Skin substitute-assisted repair shows reduced dermal fibrosis in acute  
361 human wounds validated simultaneously by histology and optical coherence tomography.  
362 *Wound repair and regeneration : official publication of the Wound Healing Society [and] the*  
363 *European Tissue Repair Society* **23**, 483-494 (2015).
- 364 32. G. D. Glinos, S. H. Verne, A. S. Aldahan, L. Liang, K. Nouri, S. Elliot, M. Glassberg, D. Cabrera  
365 DeBuc, T. Koru-Sengul, M. Tomic-Canic, I. Pastar, Optical coherence tomography for  
366 assessment of epithelialization in a human ex vivo wound model. *Wound repair and*  
367 *regeneration : official publication of the Wound Healing Society [and] the European Tissue*  
368 *Repair Society* **25**, 1017-1026 (2017).
- 369 33. S. Ud-Din, P. Foden, K. Stocking, M. Mazhari, S. Al-Habba, M. Baguneid, D. McGeorge, A.  
370 Bayat, Objective assessment of dermal fibrosis in cutaneous scarring, using optical  
371 coherence tomography, high-frequency ultrasound and immunohistomorphometry of  
372 human skin. *The British journal of dermatology* **181**, 722-732 (2019).
- 373 34. O. Ronneberger, P. Fischer, T. Brox. (Springer International Publishing, Cham, 2015), pp. 234-  
374 241.
- 375 35. E. Shelhamer, J. Long, T. Darrell, Fully Convolutional Networks for Semantic Segmentation.  
376 *IEEE Trans Pattern Anal Mach Intell* **39**, 640-651 (2017).
- 377 36. S. Kazemina, C. Baur, A. Kuijper, B. van Ginneken, N. Navab, S. Albarqouni, A.  
378 Mukhopadhyay, GANs for medical image analysis. *Artificial Intelligence in Medicine* **109**,  
379 101938 (2020).

380

## 381 **Acknowledgements**

382 **Funding:** This work was supported by an MRC Confidence in Concept Award (MC\_PC\_15046) to Ana  
383 Tiganescu and an NIHR Senior Investigator Award to Paul Stewart (NF-SI-0514-10090). **Author**  
384 **contributions:** Yin Hai Wang: Conceptualization, Data curation, Investigation, Methodology, Project  
385 administration, Resources, Software, Supervision, Validation, Visualization, Writing – review &  
386 editing, Adrian Freeman: Conceptualization, Resources, Supervision, Writing - Review & Editing, Paul  
387 M Stewart: Funding acquisition, Ramzi Ajjan: Supervision, Writing - Review & Editing, and Ana  
388 Tiganescu: Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology,  
389 Project administration, Supervision, Validation, Visualization, Writing - Original Draft, Writing -  
390 Review & Editing. **Competing interests:** nothing to disclose. **Data and materials availability:** All data

391 associated with this study are available in the main text or the supplementary materials. **Trial**  
392 **registration:** International Standard Randomised Controlled Trial Number 74621291  
393 [www.isrctn.com/ISRCTN74621291](http://www.isrctn.com/ISRCTN74621291). ClinicalTrials.gov Identifier: NCT03313297  
394 <https://clinicaltrials.gov/ct2/show/NCT03313297>.

## 395 **Figure Captions**

### 396 **Fig. 1 Machine learning outputs in day 2 and 7 wounds**

397 Representative original OCT scan outputs (A, B) and with automated annotation following machine  
398 learning (C, D). c = clot, d = dermis (intact tissue), e = epidermis, get = early granulation tissue, lgt =  
399 late granulation tissue, ne = neo-epidermis. Scale bar = 500µm.

### 400 **Fig. 2 Machine learning reliability**

401 Altman plots neo-epidermis (A), late granulation tissue (B), early granulation tissue (C) and clot (D)  
402 are shown. Intraclass correlation coefficients (ICC) and 95% limits of agreement (LoA) are displayed  
403 on each plot. Solid lines indicate the bias values and dotted lines (+2SD and -2SD) the LoA. N = 204.

### 404 **Fig. 3 Machine learning validation**

405 Correlations between machine learning outputs for maximal early granulation tissue (A, N = 51) and  
406 maximal clot depth (B, N=50) with manual measurement.

### 407 **Fig. 4 Gross Morphology and Re-epithelialization**

408 Representative images for gross morphology (A) and re-epithelialisation by manual OCT (B),  
409 quantified manually as % gross healing (C) and % re-epithelialisation (D).

### 410 **Fig. 5 Machine learning histograms**

411 Representative histograms for day 2 and day 7 post-wounding following 2- and 28-days' treatment  
412 with AZD4017 (AZD) or placebo (PBO).

### 413 **Fig. 6 Machine learning volumetric quantification**

414 Machine learning outputs for early (A) and late (B) granulation, neo-epidermis (C) and clot (D) tissue,  
415 comparing between day 2 (treatment day 2 and 30) and day 7 (treatment day 7 and 35) wounds  
416 treated with AZD4017 (AZD) or placebo (PCB).

## 417 **Supplementary Material**

418 Representative wounds for treatment day 2 placebo (S1-S3) and AZD4017 (S4-S6), treatment day 7  
419 placebo (S7-S9) and AZD4017 (S10-S12), treatment day 30 placebo (S13-S15) and AZD4017 (S16-S18)  
420 and treatment day 35 placebo (S19-S21) and AZD4017 (S22-S24).



Figure 1







Figure 2








Figure 3

A



B










Figure 4





A



PBO

AZD


B



PBO

AZD

C



D









Figure 5



PBO

AZD



Treatment day 2  
(2 days post-wounding)



Treatment day 7  
(7 days post-wounding)



Treatment day 30  
(2 days post-wounding)



Treatment day 35  
(7 days post-wounding)





Figure 6

